EA200300939A1 - Синтетические пептиды человека и фармацевтические композиции, содержащие их , для лечения системной красной волчанки - Google Patents

Синтетические пептиды человека и фармацевтические композиции, содержащие их , для лечения системной красной волчанки

Info

Publication number
EA200300939A1
EA200300939A1 EA200300939A EA200300939A EA200300939A1 EA 200300939 A1 EA200300939 A1 EA 200300939A1 EA 200300939 A EA200300939 A EA 200300939A EA 200300939 A EA200300939 A EA 200300939A EA 200300939 A1 EA200300939 A1 EA 200300939A1
Authority
EA
Eurasian Patent Office
Prior art keywords
synthetic peptides
ladge
treatment
pharmaceutical compositions
compositions containing
Prior art date
Application number
EA200300939A
Other languages
English (en)
Other versions
EA009465B1 (ru
Inventor
Эдна Мозес
Original Assignee
Йеда Рисерч Энд Дивелопмент Ко. Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Йеда Рисерч Энд Дивелопмент Ко. Лтд. filed Critical Йеда Рисерч Энд Дивелопмент Ко. Лтд.
Publication of EA200300939A1 publication Critical patent/EA200300939A1/ru
Publication of EA009465B1 publication Critical patent/EA009465B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Синтетические пептиды по крайней мере из 12 и самое большое из 30 аминокислотных остатков, включающие последовательность, состоящую из определяющего комплементарность участка (CDR) или находящуюся в CDR, содержащегося в тяжелой или легкой цепи человеческого моноклонального анти-ДНК-антитела 16/6-Id, или последовательность, полученную в результате замещения, и/или делеции, и/или присоединения одного или более аминокислотных остатков к указанной последовательности, и соли, химические производные и полимеры указанных пептидов можно использовать для иммуномодуляции ответных реакций, ассоциированных с системной красной волчанкой.Отчет о международном поиске был опубликован 2002.12.12.
EA200300939A 2001-02-26 2002-02-26 Синтетические пептиды человека и фармацевтические композиции, содержащие их, для лечения системной красной волчанки EA009465B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL14164701A IL141647A0 (en) 2001-02-26 2001-02-26 Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
PCT/IL2002/000148 WO2002067848A2 (en) 2001-02-26 2002-02-26 PEPTIDES FROM THE 16/6id ANTIBODY FOR TREATING SLE

Publications (2)

Publication Number Publication Date
EA200300939A1 true EA200300939A1 (ru) 2004-12-30
EA009465B1 EA009465B1 (ru) 2007-12-28

Family

ID=11075174

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300939A EA009465B1 (ru) 2001-02-26 2002-02-26 Синтетические пептиды человека и фармацевтические композиции, содержащие их, для лечения системной красной волчанки

Country Status (29)

Country Link
US (2) US20040127408A1 (ru)
EP (1) EP1370575B1 (ru)
JP (1) JP4316886B2 (ru)
KR (1) KR100860735B1 (ru)
CN (1) CN1309733C (ru)
AT (1) ATE346094T1 (ru)
AU (1) AU2002233618B2 (ru)
BR (1) BR0207586A (ru)
CA (1) CA2439051C (ru)
CR (1) CR7058A (ru)
CU (1) CU23276B7 (ru)
DE (1) DE60216243T2 (ru)
DK (1) DK1370575T3 (ru)
EA (1) EA009465B1 (ru)
EC (1) ECSP034743A (ru)
ES (1) ES2275832T3 (ru)
HK (1) HK1059790A1 (ru)
HR (1) HRP20030667A2 (ru)
HU (1) HU230372B1 (ru)
IL (3) IL141647A0 (ru)
IS (1) IS6908A (ru)
MX (1) MXPA03007622A (ru)
NO (1) NO331820B1 (ru)
NZ (1) NZ527499A (ru)
PL (1) PL373520A1 (ru)
PT (1) PT1370575E (ru)
SI (1) SI1370575T1 (ru)
WO (1) WO2002067848A2 (ru)
ZA (1) ZA200305874B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002033377A2 (en) * 2000-09-20 2002-04-25 Surromed, Inc. Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders
IL141647A0 (en) 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US7294687B2 (en) * 2003-01-14 2007-11-13 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
AU2004206842A1 (en) * 2003-01-14 2004-08-05 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
WO2008144041A1 (en) * 2007-05-21 2008-11-27 The Ohio State University Research Foundation Hepcidins as biomarkers for impending lupus nephritis flare
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
KR20140088837A (ko) 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
US10316075B2 (en) 2013-10-03 2019-06-11 Oregon Health & Science University Recombinant polypeptides comprising MHC class II α1 domains
CN110139659B (zh) * 2017-01-05 2023-07-28 耶达研究及发展有限公司 用于治疗干燥综合征的肽
CN112143707A (zh) * 2020-09-29 2020-12-29 广东先康达生物科技有限公司 一种治疗自身免疫细胞的免疫细胞及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127408A (en) * 1872-06-04 Improvement in tooth-powders or dentifrices
US8634A (en) * 1852-01-06 Wool-pickina machine
JPS60184098A (ja) * 1984-03-02 1985-09-19 Suntory Ltd 新規なペプチド及びこれを有効成分とする利尿剤
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5126249A (en) 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
US6066621A (en) * 1989-12-10 2000-05-23 Yeda Research And Development Co. Ltd. Synthetic peptides for the treatment of myasthenia gravis
IL92629A0 (en) * 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9017008D0 (en) 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
US6096878A (en) * 1993-05-10 2000-08-01 Japan Tobacco Inc. Human immunoglobulin VH gene segments and DNA fragments containing the same
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
GB2290293A (en) * 1994-06-08 1995-12-20 Rupert Donald Holms Preparation which inhibits the autoimmune response in HIV, or SLE, patients
IL113159A0 (en) * 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US6613536B1 (en) 1995-03-28 2003-09-02 Yeda Research And Development Co. Ltd. Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US20020054872A1 (en) 1997-03-20 2002-05-09 Yaakov Naparstek Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus
IL120503A0 (en) 1997-03-20 1997-07-13 Hadasit Med Res Service Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
WO1999031066A1 (en) * 1997-12-18 1999-06-24 Boehringer Ingelheim Pharmaceuticals, Inc. Pyridones as src family sh2 domain inhibitors
KR100261262B1 (ko) * 1998-02-03 2000-08-01 윤종용 반도체 습식 설비의 구조 및 이의 로트 로딩/언로딩 방법
US6415877B1 (en) * 1998-07-15 2002-07-09 Deep Vision Llc Subsea wellbore drilling system for reducing bottom hole pressure
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
IL141647A0 (en) 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
AU2004206842A1 (en) 2003-01-14 2004-08-05 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
US7294687B2 (en) 2003-01-14 2007-11-13 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus

Also Published As

Publication number Publication date
IL141647A0 (en) 2002-03-10
HK1059790A1 (en) 2004-07-16
NO20033718D0 (no) 2003-08-21
CN1309733C (zh) 2007-04-11
ATE346094T1 (de) 2006-12-15
IS6908A (is) 2003-08-11
MXPA03007622A (es) 2004-09-14
BR0207586A (pt) 2006-11-07
DK1370575T3 (da) 2007-01-29
HUP0600778A3 (en) 2012-09-28
WO2002067848A2 (en) 2002-09-06
SI1370575T1 (sl) 2007-04-30
AU2002233618B2 (en) 2006-12-21
HUP0600778A2 (en) 2007-01-29
CA2439051C (en) 2010-02-02
DE60216243D1 (de) 2007-01-04
NO331820B1 (no) 2012-04-10
KR20030092004A (ko) 2003-12-03
EP1370575A2 (en) 2003-12-17
US7858738B2 (en) 2010-12-28
EP1370575A4 (en) 2004-09-29
CN1503806A (zh) 2004-06-09
ECSP034743A (es) 2004-01-28
KR100860735B1 (ko) 2008-09-29
JP4316886B2 (ja) 2009-08-19
HRP20030667A2 (en) 2005-06-30
JP2005505493A (ja) 2005-02-24
PL373520A1 (en) 2005-09-05
CR7058A (es) 2004-11-01
ZA200305874B (en) 2005-08-31
NZ527499A (en) 2005-12-23
CA2439051A1 (en) 2002-09-06
US20080119390A1 (en) 2008-05-22
NO20033718L (no) 2003-10-09
IL157550A (en) 2010-05-31
PT1370575E (pt) 2007-01-31
EP1370575B1 (en) 2006-11-22
IL157550A0 (en) 2004-03-28
WO2002067848A3 (en) 2002-12-12
US20040127408A1 (en) 2004-07-01
HU230372B1 (hu) 2016-03-29
ES2275832T3 (es) 2007-06-16
DE60216243T2 (de) 2007-10-31
CU23276B7 (es) 2008-04-09
EA009465B1 (ru) 2007-12-28

Similar Documents

Publication Publication Date Title
CU23292B7 (es) Anticuerpos monoclonales humanos de ctla-4
EA200400241A1 (ru) Направленные к мишени мультимерные контрастные вещества, основанные на пептидах
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
EA200300939A1 (ru) Синтетические пептиды человека и фармацевтические композиции, содержащие их , для лечения системной красной волчанки
RU2012102323A (ru) Способ лечения ревматоидного артрита посредством лекарственного препарата на основе выделенного человеческого антитела или его антигенсвязывающего фрагмента
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
GB0315450D0 (en) Biological products
PE20050925A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
EA200300459A1 (ru) Новые, применяемые в качестве медикаментов антихолинергические средства, а также способ их получения
DK0866720T3 (da) OB-protein til forögelse af mager kropsmasse
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
BR0207151A (pt) Moléculas de aglutinação terapêuticas
EA200200875A1 (ru) Пролекарства производных имидазопиридина
EA199800230A1 (ru) Тетрагидрохинолины в качестве антагонистов nmda (n-метил-d-аспарагиновой кислоты)
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
DE60317565D1 (de) Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-liganden
EA200400670A1 (ru) Фармацевтические композиции, содержащие 3,4-пропинопергидропурины, и их применение для блокирования нейронной передачи
DK0817650T3 (da) Syntetiske peptider og farmaceutiske sammensætninger, der omfatter disse, til behandling af systemisk lupus erythematosus
EA200200798A1 (ru) Кальцилитические соединения
EA200500878A1 (ru) Кальцилитические соединения
EA199800368A1 (ru) Новые промежуточные продукты и их использование для получения n,n'-мостиковых бисиндолилмалеимидов
ID16952A (id) Bahan antagonis bradykinin heterosiklik mengandung sulfur, proses pembuatan dan penggunaannya
EA199801032A1 (ru) Белки zona pellucida для контрацепции
EA200501088A1 (ru) Цетилпиридиниевая соль противоспалительного средства и фармацевтические композиции, содержащие ее
PT524421E (pt) Herpesvirus humano tipo 6 proteina p 100, sequencias de adn correspondentes, preparacao e utilizacao

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MK4A Patent expired

Designated state(s): RU